Experienced in Malabsorption

Dr. Barbara E. Rizzardi

Internal Medicine
Sandy, UT 
Experienced in Malabsorption
Sandy, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Rizzardi is a primary care provider, practicing in Internal Medicine in Sandy, Utah. Dr. Rizzardi is rated as an Experienced provider by MediFind in the treatment of Malabsorption. Her top areas of expertise are Celiac Disease, Malabsorption, Diphtheria, and Tetanus.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Malabsorption.

Specialties
Internal Medicine
Licenses
Internal Medicine in UT
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Sandy, UT 84093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drug: KAN-101
Study Phase: Phase 1
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Phase I/II Observer-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Hong Kong/125/2017-like (H7N9) Virus Vaccine With AS03 Adjuvant System, Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
A Phase I/II Observer-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Hong Kong/125/2017-like (H7N9) Virus Vaccine With AS03 Adjuvant System, Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Combination product
Study Drugs: Abaloparatide solid microstructured transdermal system, Abaloparatide subcutaneous
Study Phase: Phase 3
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: PSD502
Study Phase: Phase 2
CI03: A Clinical Investigation to Evaluate Efficacy of the J3 Bioscience Lubricating Intravaginal Ring VR101 as a Personal Lubricant Device in Women
CI03: A Clinical Investigation to Evaluate Efficacy of the J3 Bioscience Lubricating Intravaginal Ring VR101 as a Personal Lubricant Device in Women
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

3 Total Publications

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Journal: Diabetes, obesity & metabolism
Published: December 13, 2023
Similar Doctors
Experienced in Malabsorption
Dr. Bharani G. Srinivasan
Internal Medicine
Experienced in Malabsorption
Dr. Bharani G. Srinivasan
Internal Medicine
Riverton, UT 
 (9.2 miles away)
801-285-4646
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bharani Srinivasan is a primary care provider, practicing in Internal Medicine in Riverton, Utah. Dr. Srinivasan is rated as an Experienced provider by MediFind in the treatment of Malabsorption. Her top areas of expertise are Grass Allergy, Celiac Disease, Malabsorption, and Rabson-Mendenhall Syndrome. Dr. Srinivasan is currently accepting new patients.

Experienced in Malabsorption
Dr. Gloria R. Gonzales
Internal Medicine
Experienced in Malabsorption
Dr. Gloria R. Gonzales
Internal Medicine

Granger Medical Clinic PC

West Valley City, UT 
 (9.6 miles away)
801-965-3600
Languages Spoken:
English, Filipino, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gloria Gonzales is a primary care provider, practicing in Internal Medicine in West Valley City, Utah. Dr. Gonzales is rated as an Experienced provider by MediFind in the treatment of Malabsorption. Her top areas of expertise are Osteomyelitis in Children, Type 2 Diabetes (T2D), Infant Hyperglycemia, and Hypothyroidism. Dr. Gonzales is currently accepting new patients.

Dr. Kent G. Marshall
Internal Medicine
Dr. Kent G. Marshall
Internal Medicine
700 W 800 N Ste 400, 
Orem, UT 
 (20.4 miles away)
801-221-8811
Languages Spoken:
English
See accepted insurances

Kent Marshall is a primary care provider, practicing in Internal Medicine in Orem, Utah. Dr. Marshall is rated as an Experienced provider by MediFind in the treatment of Malabsorption. His top areas of expertise are Type 2 Diabetes (T2D), Obesity in Children, Osteomyelitis in Children, and Hypothyroidism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rizzardi's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile